Peripheral absolute lymphocyte count and survival of patients with triple-negative breast cancer: a meta-analysis
Abstract
BackgroundPeripheral absolute lymphocyte count (ALC) has emerged as a potential prognostic biomarker in patients with triple-negative breast cancer (TNBC), but the available evidence remains inconsistent. We performed a systematic review and meta-analysis to evaluate the association between peripheral ALC and survival outcomes in patients with TNBC.MethodsPubMed, Embase, Web of Science, Wanfang, and China National Knowledge Infrastructure (CNKI) were systematically searched from database inception to June 20, 2026. Observational studies evaluating the association between peripheral ALC and survival in adult patients with TNBC were included. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models.ResultsTen studies involving 1,799 patients with TNBC were included. Low peripheral ALC was significantly associated with poorer overall survival (OS; eight studies, HR 2.22, 95% CI 1.73-2.85; I2 = 0%) and progression-free survival (PFS; six studies, HR 2.09, 95% CI 1.61-2.72; I2 = 4%). Subgroup analyses showed that no statistically significant subgroup differences in the association between low ALC and OS were detected according to tumor stage (stage I-III vs. stage IV), timing of ALC measurement (pretreatment vs. during treatment), method for determining the ALC cutoff (receiver operating characteristic curve analysis, median value, or predefined cutoff), ALC cutoff value (< 1.5 vs. ≥ 1.5 × 109/L), follow-up duration, analytic model (univariate vs. multivariate), or study quality (all p for subgroup differences > 0.05).ConclusionsLow peripheral ALC is associated with poorer OS and PFS in patients with TNBC. However, given the predominantly retrospective and geographically concentrated evidence, the potential prognostic utility of ALC requires validation in prospective studies across more diverse populations.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420261467726.
Related
- Peripheral Lymphocyte Subsets Predict Efficacy and Overall Survival in Gastric Cancer Patients Receiving Preoperative Chemotherapy: A Retrospective Cohort Study
- Tumour region identification guided scoring (TRIGS) and foundation model-based Tumour Infiltrating Lymphocyte scoring are prognostic for pathological complete response/event free survival in the triple negative patients in the PARTNER randomized controlled trial
- Association between absolute lymphocyte count and outcomes of radiotherapy combined with immunotherapy in elderly patients with inoperable esophageal squamous cell carcinoma
- Analysis of the Correlation Between Peripheral Blood Lymphocyte Subsets and Pathological Complete Response Rate in Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy
- Association of dynamic changes in platelet-to-lymphocyte ratio during chemotherapy with survival in patients with non-small cell lung cancer
BibTeX
@article{yang2026peripheral,
title = {{Peripheral absolute lymphocyte count and survival of patients with triple-negative breast cancer: a meta-analysis}},
author = {Huihui Yang and Chuanxin Ye and Taikao Qin and Zhihuang Lei and Qin Rong and Yunzhu Zhou and Shuangyu Xie and Bin Lian},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1956778},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1956778},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Peripheral absolute lymphocyte count and survival of patients with triple-negative breast cancer: a meta-analysis
AU - Huihui Yang
AU - Chuanxin Ye
AU - Taikao Qin
AU - Zhihuang Lei
AU - Qin Rong
AU - Yunzhu Zhou
AU - Shuangyu Xie
AU - Bin Lian
PY - 2026
DA - 2026/11/02
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1956778
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1956778
AB - BackgroundPeripheral absolute lymphocyte count (ALC) has emerged as a potential prognostic biomarker in patients with triple-negative breast cancer (TNBC), but the available evidence remains inconsistent. We performed a systematic review and meta-analysis to evaluate the association between peripheral ALC and survival outcomes in patients with TNBC.MethodsPubMed, Embase, Web of Science, Wanfang, and China National Knowledge Infrastructure (CNKI) were systematically searched from database inception to June 20, 2026. Observational studies evaluating the association between peripheral ALC and survival in adult patients with TNBC were included. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models.ResultsTen studies involving 1,799 patients with TNBC were included. Low peripheral ALC was significantly associated with poorer overall survival (OS; eight studies, HR 2.22, 95% CI 1.73-2.85; I2 = 0%) and progression-free survival (PFS; six studies, HR 2.09, 95% CI 1.61-2.72; I2 = 4%). Subgroup analyses showed that no statistically significant subgroup differences in the association between low ALC and OS were detected according to tumor stage (stage I-III vs. stage IV), timing of ALC measurement (pretreatment vs. during treatment), method for determining the ALC cutoff (receiver operating characteristic curve analysis, median value, or predefined cutoff), ALC cutoff value (< 1.5 vs. ≥ 1.5 × 109/L), follow-up duration, analytic model (univariate vs. multivariate), or study quality (all p for subgroup differences > 0.05).ConclusionsLow peripheral ALC is associated with poorer OS and PFS in patients with TNBC. However, given the predominantly retrospective and geographically concentrated evidence, the potential prognostic utility of ALC requires validation in prospective studies across more diverse populations.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420261467726.
SN - 2234-943X
ER -